Please login to the form below

Not currently logged in
Email:
Password:

TerSera Therapeutics

This page shows the latest TerSera Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Grünenthal buys Zomig rights as AZ slimming drive continues

Grünenthal buys Zomig rights as AZ slimming drive continues

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

Latest news

  • AZ agrees to $320m deal for Zoladex AZ agrees to $320m deal for Zoladex

    AZ agrees to $320m deal for Zoladex. TerSera Therapeutics acquires rights to oncology drug in US and Canada. ... AstraZeneca has sold the rights to its big-selling cancer drug Zoladex in Canada and the US to TerSera Therapeutics, as the UK firm moves to

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics